Navigation Links
GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.
Date:2/23/2009

LIBERTY CORNER, N.J., Feb. 23 /PRNewswire/ -- GeneraMedix, Inc. announced today that it has entered into a definitive agreement to sell its improved formulation of epoprostenol sodium for the intravenous treatment of pulmonary arterial hypertension (PAH) to Actelion LTD., a biopharmaceutical company with its headquarters in Allschwil/Basel, Switzerland. Financial terms of the deal were not disclosed.

"This sale speaks directly to our company's ongoing commitment to serving the unique needs of patients in specialty markets, in this case pulmonary arterial hypertension (PAH)," said Ron Quadrel, CEO, of GeneraMedix, Inc. "I'm also very pleased to conclude this transaction with Actelion, a company that is committed to improving the lives of PAH patients through improved treatment options," added Quadrel.

On June 27, 2008, the U.S. FDA approved Epoprostenol for Injection (1.5 mg/ml vial) for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

The new formulation of epoprostenol uses non-proprietary diluents, and once reconstituted prior to use, it may be stored for up to 48 hours at 25 degrees Celsius or for five days in the refrigerator at 2-8 degrees Celsius. Global patents have been filed for this new formulation. Actelion will be responsible for global development, registration and commercialization for the product.

"We are very pleased to acquire this innovative product as it builds on our commitment to PAH therapy. Actelion has always led the drive in developing innovative therapies for PAH patients and treating physicians, and we believe this new improved formulation could potentially play a significant role in the management of PAH," stated Jean-Paul Clozel, M.D. and CEO of Actelion.'/>"/>

SOURCE GeneraMedix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
2. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
3. Abbott Announces 11 Percent Increase in Quarterly Dividend
4. Shire Announces Opening of Office in Japan
5. InterMune Announces Issuance of U.S. Patent for ITMN-191
6. Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team
7. Psychemedics Corporation Announces 2008 Year End Results
8. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
9. Amicus Therapeutics Announces Change to Board of Directors
10. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast
11. Obio Pharmaceutical Announces Product Growth Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... New York (PRWEB) July 25, 2014 ... Market Research, "Biological Drugs Market - Global Industry Analysis, ... the global biological drugs market is estimated at USD ... at a CAGR of 10.1% from 2014 to 2020, ... in 2020. , The biological drugs market is witnessing ...
(Date:7/25/2014)... PA (PRWEB) July 25, 2014 The ... Call for Topics for Conferee Networking. These two-hour sessions ... interests to meet and resolve problems, discuss new techniques, ... The deadline to submit a topic for consideration is ... pittcon.org . The Conferee Networking committee will review ...
(Date:7/25/2014)... Israel , July 25, 2014  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, today announced financial results for ... Half 2014 Financial Summary: , Reported cash and ... compared with $137,000 at December 31, 2013.  , ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2
... de Heer, professor of physics at the Georgia Institute of ... Boston today. De Heer was cited by the society for ... graphene." The MRS Medal recognizes an exceptional achievement in materials ... awarded for a specific outstanding recent discovery or advancement that ...
... (DARPA) has awarded the UCLA Henry Samueli School of ... research on a technology known as non-volatile logic, which ... even while powered off, then start up and run ... broad implications across a range of technologies, including portable ...
... Dec. 2, 2010 Physicians at Thomas Jefferson University ... the potential for fully automated interpretation of coronary CT ... rule out coronary artery disease (CAD) in the major ... was presented in Chicago at the Radiological Society of ...
Cached Biology Technology:Georgia Tech's Walt de Heer awarded Materials Research Society Medal 2UCLA receives $8.4 million to lead research on ultra-low-power, non-volatile logic technologies 2Rcadia COR Analyzer System Safely Rules Out Coronary Artery Disease in Main Coronary Arteries and Branch Vessels 2
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
(Date:7/25/2014)... for Medical Research have identified the functions of ... to triggering the mating process in mice. , They ... detect pheromones that indicate when a female is present. ... the female mouse is ovulating and ready to mate. ... Stowers, researchers believe mice developed this system through evolution ...
(Date:7/25/2014)... , July 25, 2014 Biometrics ... are turning to digital technology for online & commerce ... Google Inc. (NASDAQ: GOOG ), LifeLock Inc. ... V ), Apple Inc. (NASDAQ: AAPL ... Inc., (OTCQB: NXTD) a biometric authentication company focused on ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
... Osteoporosis Foundation (IOF) has issued a literature review ... safety of two minimally invasive techniques for vertebral ... kyphoplasty (BKP). The review also lists important recommendations ... highlights research questions still unresolved. Vertebral fractures, ...
... availability of the newest edition of its authoritative reference ... 10th edition, is available in both print and, for ... edition of the Manual of Clinical Microbiology marks a ... says Editor-in-Chief James Versalovic of Texas Children,s Hospital. "For ...
... found that the risk of death and cardiovascular disease, ... intense or conventional. They did find, however, that when ... intensive level, the chance of damaging small blood vessels ... eyes and kidneys, is reduced. But aiming for this ...
Cached Biology News:IOF urges systematic osteoporosis management after vertebral fracture augmentation 2New edition of Manual of Clinical Microbiology offers digital access 2Type 2 diabetes: 'Intensive' versus 'conventional' blood glucose control -- no clear picture 2
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
...
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
Biology Products: